Vivos Therapeutics (VVOS) Net Cash Flow Growth (3y) (2023 - 2026)
Vivos Therapeutics (VVOS) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 42.74% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | -87.88% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | -65.12% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -48.90% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 129.29% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 33.47% |
| 10 | Vivos Therapeutics | 8.16 Mn | 5.93 Mn | 3.06 Mn | -71.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -71.68% |
| Dec 31, 2025 | 31.84% |
| Sep 30, 2025 | 39.12% |
| Jun 30, 2025 | -22.62% |
| Mar 31, 2025 | 14.28% |
| Dec 31, 2024 | 77.54% |
| Sep 30, 2024 | 52.77% |
| Jun 30, 2024 | -40.26% |
| Mar 31, 2024 | 30.67% |
| Dec 31, 2023 | -65.18% |
| Sep 30, 2023 | -66.30% |
| Jun 30, 2023 | -130.51% |
| Mar 31, 2023 | 127.89% |